BBBruce Brown

Bruce Brown

*This is an algorithmically generated author record based on publicly available information.

Bruce Brown has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analytical Evaluation of SARS CoV 2 Spike Protein Stability across Routine Aliquoting and Freezing Methods

    by Ruturaj R. Masvekar, Gabriela Mansano Do Nascimento, Jaikin Harrell, Aliyah H. Remoroza, Hannah Ambrose, Matthew Drew, Bruce Brown, Troy J. Kemp, Shweta Jain, Ligia A. Pinto

    Serological assays are essential for infectious disease surveillance and vaccine evaluation because they detect antibody responses that persist beyond the period of active viral replication. The reliability of these assays, however, depends heavily on the structural and functional stability of the antigens used. Recombinant proteins—such as the SARS‑CoV‑2 Spike—are vulnerable to degradation from suboptimal handling, storage, and repeated freeze–thaw cycles, which can compromise assay performance. To address this concern, we systematically assessed the impact of three commonly used aliquoting and freezing approaches on the long‑term stability of a recombinant SARS‑CoV‑2 Spike protein: (1) aliquoting on wet ice followed by storage at −80 °C, (2) aliquoting on dry ice followed by storage at −80 °C, and (3) aliquoting on dry ice followed by snap‑freezing in a methanol–dry ice bath. Aliquots from two manufacturing lots were evaluated over six months using multiple quality metrics, including purity, structural integrity [Analytical Size Exclusion Chromatography (AnSEC) and Thermal Shift Assay (TSA)], and functional performance in a validated IgG ELISA. Across all conditions and time points, antigen purity remained within the ideal A260/A280 range (0.6–0.8), with minimal nucleic acid contamination. ELISA performance demonstrated consistently low background and high sensitivity, specificity, and precision. Structural analyses confirmed stable protein size and conformation (AnSEC elution peaks within ±1.0 mL of baseline) and unchanged thermal stability (Tm within ±2.0 °C). These findings indicate that all tested methodologies effectively preserved antigen integrity under controlled laboratory conditions, providing a foundation for standardized SOPs while acknowledging that real‑world variability may influence outcomes.